Abstract:ID 18908 Poster Board 186 Pregnane X receptor (PXR, NR1I2), a ligand-activated transcription factor, is relatively abundant in liver and intestine. Previous studies have demonstrated that PXR activation inhibits liver fibrosis, but the specific mechanisms still remain unclear. Leukocyte cell-derived chemotaxin 2 (LECT2), a downstream target of β-catenin/ T cell-specific factor 4 (TCF4) signaling, is a small-molecule protein secreted by hepatocytes. Recent study illustrated that LECT2 produced by hepatocytes participated in the progression of hepatic fibrosis by regulating angiogenesis. In the current study, we aimed to investigate whether PXR activation attenuate liver fibrosis by inhibiting LECT2 and explore its impact on β-catenin/TCF4 signaling. Additionally, we also aimed to unveil the critical role of β-catenin/TCF4-LECT2 axis in liver fibrosis and demonstrate whether PXR activation alleviates hepatic fibrosis via inhibiting β-catenin/TCF4-LECT2 axis. In the current study, carbon tetrachloride (CCl4) was used to induce liver fibrosis in C57BL/6 mice. The results showed that mouse PXR agonist pregnenolone-16α-carbonitrile (PCN) significantly attenuated hepatic fibrosis by suppressing the expression of α-smooth muscle actin (α-SMA), Collagen ? and platelet endothelial cell adhesion molecule-1 (CD31). Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) and CD31 staining indicated that PXR activation inhibited sinusoids capillarization and central angiogenesis. Besides, immunohistochemical (IHC) staining and western blot analysis indicated that LECT2 and nuclear β-catenin were significantly downregulated after PXR activation, while total β-catenin and TCF4 didn’t alter significantly. Furthermore, reporter gene assay was performed and suggested that PXR activation inhibited the transcriptional activation of LECT2 by β-catenin/TCF4. PXR activation disrupted the interaction between β-catenin and TCF4. Co-Immunoprecipitation (Co-IP) assays further indicated that PXR potentially interacted with β-catenin and TCF4 simultaneously. Moreover, to clarify whether disrupting β-catenin/TCF4 interaction alleviated liver fibrosis, β-catenin/TCF4 inhibitor LF3 was used to evaluate its effect on liver fibrosis. The results showed the inhibition of β-catenin/TCF4 interaction decreased the expression level of LECT2 and alleviated liver fibrosis. In addition, AAV-Lect2 mice was used and we found that PXR activation failed to protect liver from fibrosis in AAV-Lect2 mice, which further confirmed that PXR attenuated hepatic fibrosis by inhibiting LECT2. Finally, we clarified that long-term treatment of PCN had no risk for carcinogenesis or promoting tumor formation induced by diethylnitrosamine (DEN), indicating the safety of long-term activation of PXR. Taken together, this study demonstrated a new mechanism that PXR attenuated liver fibrosis by disrupting β-catenin/TCF4 interaction and suppressing the expression level of LECT2. The crosstalk between PXR and β-catenin/TCF4 signaling was also clarified. These findings provide new evidence and theoretical basis for PXR as potential drug target for liver fibrosis.

Paeoniflorin promotes PPARγ expression to suppress HSCs activation by inhibiting EZH2-mediated histone H3K27 trimethylation

Paeoniflorin Alleviates Liver Fibrosis by Inhibiting HIF-1α Through Mtor-Dependent Pathway.

Paeoniflorin Modulates Oxidative Stress, Inflammation and Hepatic Stellate Cells Activation to Alleviate CCl4-induced Hepatic Fibrosis by Upregulation of Heme Oxygenase-1 in Mice

Paeonol alleviates CCl4-induced liver fibrosis through suppression of hepatic stellate cells activation via inhibiting the TGF-β/Smad3 signaling

Paeoniflorin Coordinates Macrophage Polarization and Mitigates Liver Inflammation and Fibrogenesis by Targeting the NF-[Formula: see text]B/HIF-1α Pathway in CCl4-Induced Liver Fibrosis.

Paeonol Attenuated Vascular Fibrosis Through Regulating Treg/Th17 Balance in a Gut Microbiota-Dependent Manner

Periplaneta americana extract attenuates hepatic fibrosis progression by inhibiting collagen synthesis and regulating the TGF-β1/Smad signaling pathway

PPARβ/δ attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells

Fluorofenidone Attenuates Hepatic Fibrosis By Suppressing The Proliferation And Activation Of Hepatic Stellate Cells

Paeoniflorin Alleviates Non-Alcoholic Steatohepatitis in Rats: Involvement with the ROCK/NF-κB Pathway.

Protective effect of paeoniflorin on rat with chronic liver injury and fibrosis

The combination of paeoniflorin and metformin synergistically inhibits the progression of liver fibrosis in mice

MDP Induces the Senescence of Activated Hepatic Stellate Cells Through Regulating Ago2/miR-708/ZEB1/p53 Pathway

Paeoniflorin-free subfraction of Paeonia lactiflora Pall. shows the potential of anti-hepatic fibrosis: an integrated analysis of network pharmacology and experimental validation

Paeonol ameliorates hyperlipidemia and autophagy in mice by regulating Nrf2 and AMPK/mTOR pathways

Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression

PXR Activation Attenuates Liver Fibrosis by Down-Regulating LECT2 and Disrupting -Catenin/tcf4 Interaction

Effect of PPARγ on signal transduction of hepatic stellate cells in liver fibrosis

Paeoniflorin, a Natural Product With Multiple Targets in Liver Diseases—A Mini Review

Paeoniflorin Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice